{"product_id":"0512hk-business-model-canvas","title":"Grand Pharmaceutical Group Limited (0512.HK): Canvas Business Model","description":"\u003cp\u003eGrand Pharmaceutical Group Limited stands at the forefront of the pharmaceutical industry, crafting innovative solutions that enhance healthcare outcomes. With a robust Business Model Canvas that highlights key partnerships, activities, and resources, this company is engineered for success in a competitive landscape. Dive deeper to uncover the intricacies of their operations, from revenue streams to customer engagement strategies, and see how they deliver value in today's dynamic market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eGrand Pharmaceutical Group Limited engages in various strategic partnerships to enhance its operational capabilities and market reach. The following key partnerships play a crucial role in the company’s business model.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions and Universities\u003c\/h3\u003e\n\n\u003cp\u003eCollaboration with research institutions and universities is vital for Grand Pharmaceutical to foster innovation and develop new products. The company has established partnerships with various academic entities to leverage cutting-edge research and development. For instance, in 2022, Grand Pharmaceutical collaborated with Peking University to develop new drug formulations, leading to an estimated increase of \u003cstrong\u003e15%\u003c\/strong\u003e in their research output.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\n\u003cp\u003eThe procurement of high-quality raw materials is essential for Grand Pharmaceutical's production processes. The company has built long-term relationships with suppliers to ensure the consistent supply of pharmaceutical ingredients. As of 2023, Grand Pharmaceutical sources approximately \u003cstrong\u003e60%\u003c\/strong\u003e of its raw materials from leading suppliers in China and internationally. This strategic sourcing has enabled the company to maintain a competitive edge in pricing and quality.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eSupplier Name\u003c\/th\u003e\n        \u003cth\u003eLocation\u003c\/th\u003e\n        \u003cth\u003ePercentage of Supply\u003c\/th\u003e\n        \u003cth\u003eYear Established\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eChina National Pharmaceutical Group\u003c\/td\u003e\n        \u003ctd\u003eBeijing, China\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e1998\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHunan Dihua Pharmaceutical\u003c\/td\u003e\n        \u003ctd\u003eHunan, China\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e2005\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eActive Pharmaceutical Ingredients Inc.\u003c\/td\u003e\n        \u003ctd\u003eCalifornia, USA\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e2010\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAlfa Aesar\u003c\/td\u003e\n        \u003ctd\u003eMassachusetts, USA\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e1962\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLonza Group\u003c\/td\u003e\n        \u003ctd\u003eSwitzerland\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e1897\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\n\u003cp\u003eGiven the highly regulated nature of the pharmaceutical industry, partnerships with regulatory bodies are essential. Grand Pharmaceutical collaborates with national health authorities such as the National Medical Products Administration (NMPA) in China. In 2022, the company received approval for \u003cstrong\u003e8\u003c\/strong\u003e new products, significantly enhancing its market presence. This regulatory alignment helps mitigate risks associated with compliance and accelerates product launches.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Partners\u003c\/h3\u003e\n\n\u003cp\u003eDistribution is a critical component of Grand Pharmaceutical's business strategy. The company partners with multiple distributors to ensure the efficient delivery of its products to healthcare providers. In 2023, Grand Pharmaceutical engaged with over \u003cstrong\u003e30\u003c\/strong\u003e distribution partners, covering more than \u003cstrong\u003e2,000\u003c\/strong\u003e hospitals and pharmacies across China. This network is projected to increase sales reach by \u003cstrong\u003e20%\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eDistribution Partner\u003c\/th\u003e\n        \u003cth\u003eCoverage Area\u003c\/th\u003e\n        \u003cth\u003eYearly Volume (Units)\u003c\/th\u003e\n        \u003cth\u003ePartnership Start Year\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSinopharm Group\u003c\/td\u003e\n        \u003ctd\u003eNational\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e500,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e2015\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eShanghai Pharmaceutical\u003c\/td\u003e\n        \u003ctd\u003eEastern China\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e300,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e2018\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGuangzhou Pharmaceutical\u003c\/td\u003e\n        \u003ctd\u003eSouthern China\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e2019\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eYunnan Baiyao Group\u003c\/td\u003e\n        \u003ctd\u003eSouthwestern China\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e2020\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTianjin Pharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003eNorthern China\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eGrand Pharmaceutical Group Limited engages in several key activities essential to its operations and value delivery. The company focuses primarily on drug research and development, manufacturing and production, quality assurance, and marketing and sales.\u003c\/p\u003e\n\n\u003ch3\u003eDrug Research and Development\u003c\/h3\u003e\n\u003cp\u003eResearch and development (R\u0026amp;D) is a fundamental component of Grand Pharmaceutical's strategy. In 2022, the company reported an R\u0026amp;D expenditure of approximately \u003cstrong\u003eRMB 1.32 billion\u003c\/strong\u003e, representing around \u003cstrong\u003e12%\u003c\/strong\u003e of its total revenue. This investment underscores the firm's commitment to innovation, with over \u003cstrong\u003e200\u003c\/strong\u003e ongoing research projects aimed at new drug formulations, particularly in oncology and infectious diseases.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing and Production\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical operates several manufacturing facilities that adhere to stringent regulatory standards. The company has a total production capacity of around \u003cstrong\u003e3 billion units\u003c\/strong\u003e annually. They produced over \u003cstrong\u003e1.5 billion units\u003c\/strong\u003e in 2022 alone. The facilities are equipped with advanced technology, enabling efficient mass production and flexibility to scale up as needed. The company reported revenues of approximately \u003cstrong\u003eRMB 7.6 billion\u003c\/strong\u003e from this segment in the last fiscal year.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Assurance\u003c\/h3\u003e\n\u003cp\u003eQuality assurance is integral to Grand Pharmaceutical's operational framework. The company employs over \u003cstrong\u003e400 quality control professionals\u003c\/strong\u003e and conducts over \u003cstrong\u003e100,000 tests\u003c\/strong\u003e annually to ensure compliance with regulatory standards. In 2022, the quality assurance department saw a budget allocation of approximately \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e, emphasizing its importance in maintaining product integrity and safety.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical's marketing and sales strategies are designed to enhance brand awareness and drive product uptake. In 2022, the marketing expenses were approximately \u003cstrong\u003eRMB 800 million\u003c\/strong\u003e, reflecting a strategic push into emerging markets. The sales team expanded its reach, achieving a total sales revenue of about \u003cstrong\u003eRMB 10 billion\u003c\/strong\u003e in the same year. The company reported a year-on-year sales growth of \u003cstrong\u003e15%\u003c\/strong\u003e in key therapeutic areas.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Activity\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancials (RMB)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDrug R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003eOngoing projects: 200+\u003c\/td\u003e\n        \u003ctd\u003eR\u0026amp;D expenditure: 1.32 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing\u003c\/td\u003e\n        \u003ctd\u003eProduction capacity: 3 billion units\u003c\/td\u003e\n        \u003ctd\u003eRevenue from manufacturing: 7.6 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuality Assurance\u003c\/td\u003e\n        \u003ctd\u003eQuality control professionals: 400+\u003c\/td\u003e\n        \u003ctd\u003eQuality assurance budget: 150 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Sales\u003c\/td\u003e\n        \u003ctd\u003eMarketing expenses: 800 million\u003c\/td\u003e\n        \u003ctd\u003eTotal sales revenue: 10 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eGrand Pharmaceutical Group Limited\u003c\/strong\u003e operates predominantly in the pharmaceutical sector, focusing on research, development, production, and distribution of medications. The company's resources are crucial for its operational success and its ability to deliver value to customers.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical Group holds a robust portfolio of intellectual property, including patents that safeguard its innovative drugs. As of the latest reports, the company has over \u003cstrong\u003e200 patents\u003c\/strong\u003e granted globally. Notably, the company focuses on therapeutic areas such as oncology, cardiovascular, and anti-infectives, which have substantial market potential.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\u003cp\u003eThe company employs a diverse and skilled workforce of approximately \u003cstrong\u003e8,000 employees\u003c\/strong\u003e as of 2023. This includes over \u003cstrong\u003e1,200 researchers\u003c\/strong\u003e dedicated to advancing pharmaceutical technology and innovation. Grand Pharmaceutical Group invests significantly in employee development, evidenced by a training budget of \u003cstrong\u003e¥50 million\u003c\/strong\u003e (approximately \u003cstrong\u003e$7.5 million\u003c\/strong\u003e) annually to enhance skills and competencies.\u003c\/p\u003e\n\n\u003ch3\u003eProduction Facilities\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical operates several state-of-the-art production facilities across China, designed to comply with international regulatory standards. The company’s flagship manufacturing plant in Shenzhen covers an area of \u003cstrong\u003e100,000 square meters\u003c\/strong\u003e and has an annual production capacity of over \u003cstrong\u003e1 billion units\u003c\/strong\u003e of medications. Investments in these facilities reached \u003cstrong\u003e¥500 million\u003c\/strong\u003e (around \u003cstrong\u003e$75 million\u003c\/strong\u003e) in the last fiscal year to upgrade technology and expand capacity.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development Labs\u003c\/h3\u003e\n\u003cp\u003eThe commitment to R\u0026amp;D is reflected in the company’s investments, which amounted to \u003cstrong\u003e15% of total revenue\u003c\/strong\u003e in the last financial year, translating to approximately \u003cstrong\u003e¥600 million\u003c\/strong\u003e (about \u003cstrong\u003e$90 million\u003c\/strong\u003e). The R\u0026amp;D centers are equipped with advanced technologies, including high-throughput screening and molecular modeling software, to accelerate drug discovery. The company has also established partnerships with leading universities to foster innovation.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Resource\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eStatistical Data\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIntellectual Property\u003c\/td\u003e\n        \u003ctd\u003ePatents related to innovative drugs\u003c\/td\u003e\n        \u003ctd\u003eOver 200 patents granted globally\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n        \u003ctd\u003eDiverse team including researchers\u003c\/td\u003e\n        \u003ctd\u003eApproximately 8,000 employees, 1,200+ researchers\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduction Facilities\u003c\/td\u003e\n        \u003ctd\u003eManufacturing plants compliant with regulations\u003c\/td\u003e\n        \u003ctd\u003e100,000 sq. meters, over 1 billion units\/year production capacity\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development Labs\u003c\/td\u003e\n        \u003ctd\u003eAdvanced labs for drug discovery and innovation\u003c\/td\u003e\n        \u003ctd\u003eInvestment of ¥600 million in R\u0026amp;D, 15% of total revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eGrand Pharmaceutical Group Limited\u003c\/strong\u003e emphasizes value propositions that cater to its diverse customer base, focusing on delivering high-quality products and innovative solutions. This approach not only addresses customer needs but also sets the company apart in the competitive pharmaceutical landscape.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality pharmaceutical products\u003c\/h3\u003e\n\n\u003cp\u003eThe cornerstone of Grand Pharmaceutical's value proposition is its commitment to \u003cstrong\u003ehigh-quality pharmaceutical products\u003c\/strong\u003e. The company dedicates substantial resources to research and development to ensure the efficacy and safety of its offerings. In 2022, the company reported that approximately \u003cstrong\u003e16.3% of its revenue\u003c\/strong\u003e, amounting to about \u003cstrong\u003eRMB 1.25 billion\u003c\/strong\u003e, was directed towards R\u0026amp;D efforts. Their portfolio includes over \u003cstrong\u003e200 varieties\u003c\/strong\u003e of pharmaceutical products spanning various therapeutic areas, including oncology, cardiology, and neuropsychiatry.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative treatment solutions\u003c\/h3\u003e\n\n\u003cp\u003eInnovation is another critical aspect of Grand Pharmaceutical's value proposition. The company has launched several novel therapies in recent years, most notably in the oncology segment. In 2023, they introduced \u003cstrong\u003e5 new treatment regimens\u003c\/strong\u003e that target specific cancer types, resulting in an overall patent portfolio expansion to \u003cstrong\u003e80 patents\u003c\/strong\u003e related to drug formulation and delivery methods. This focus on innovation has contributed to a \u003cstrong\u003e15% increase\u003c\/strong\u003e in oncology sales year-on-year, highlighting the market's positive response to these advancements.\u003c\/p\u003e\n\n\u003ch3\u003eCompliance with regulatory standards\u003c\/h3\u003e\n\n\u003cp\u003eGrand Pharmaceutical ensures compliance with both local and international regulatory standards. The company adheres to the \u003cstrong\u003eGood Manufacturing Practices (GMP)\u003c\/strong\u003e as set by the National Medical Products Administration (NMPA) and the \u003cstrong\u003eU.S. Food and Drug Administration (FDA)\u003c\/strong\u003e. In 2022, the company achieved a compliance rate of \u003cstrong\u003e99.5%\u003c\/strong\u003e in FDA audits, which significantly enhances its credibility in international markets. This level of compliance not only mitigates risks but also serves as a selling point for customers looking for dependable pharmaceutical suppliers.\u003c\/p\u003e\n\n\u003ch3\u003eRobust supply chain\u003c\/h3\u003e\n\n\u003cp\u003eThe strength of Grand Pharmaceutical's value proposition is further reinforced by its \u003cstrong\u003erobust supply chain\u003c\/strong\u003e. The company has invested in logistics and distribution networks that ensure timely delivery of products. They reported a \u003cstrong\u003e25% reduction\u003c\/strong\u003e in lead times from manufacturing to distribution over the past two years, attributed to enhancements in their operational processes. This efficiency has led to a customer satisfaction rate of \u003cstrong\u003e92%\u003c\/strong\u003e, as measured in their latest customer feedback survey.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eValue Proposition Component\u003c\/th\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n        \u003cth\u003eImpact on Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHigh-quality pharmaceutical products\u003c\/td\u003e\n        \u003ctd\u003e16.3% of revenue in R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003eRMB 1.25 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eInnovative treatment solutions\u003c\/td\u003e\n        \u003ctd\u003e5 new treatment regimens launched\u003c\/td\u003e\n        \u003ctd\u003e15% increase in oncology sales\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCompliance with regulatory standards\u003c\/td\u003e\n        \u003ctd\u003e99.5% compliance rate in FDA audits\u003c\/td\u003e\n        \u003ctd\u003eEnhanced credibility in international markets\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRobust supply chain\u003c\/td\u003e\n        \u003ctd\u003e25% reduction in lead times\u003c\/td\u003e\n        \u003ctd\u003eCustomer satisfaction rate: 92%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eGrand Pharmaceutical Group Limited emphasizes direct engagement as a critical component of its customer relations strategy. The company employs over \u003cstrong\u003e1,000 medical representatives\u003c\/strong\u003e who actively promote products and foster relationships with healthcare professionals. This substantial workforce is essential for maintaining personalized interactions and ensuring that clients receive tailored solutions tailored to their needs.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, Grand Pharmaceutical has invested in robust customer support services, which include a dedicated \u003cstrong\u003e24\/7 hotline\u003c\/strong\u003e that addresses inquiries and concerns related to their products. In the fiscal year 2022, their customer support operations reportedly handled approximately \u003cstrong\u003e150,000 inquiries\u003c\/strong\u003e, maintaining an impressive response rate with \u003cstrong\u003e90%\u003c\/strong\u003e of calls resolved on the first contact.\u003c\/p\u003e\n\n\u003cp\u003eIn terms of customer loyalty, the company has instituted loyalty programs for healthcare providers that offer incentives based on prescription volumes. In 2023, it was noted that participation in these programs rose by \u003cstrong\u003e25%\u003c\/strong\u003e, directly correlating with an increase in sales by \u003cstrong\u003e15%\u003c\/strong\u003e across their product lines, particularly in chronic disease medications.\u003c\/p\u003e\n\n\u003cp\u003eMoreover, Grand Pharmaceutical conducts educational workshops aimed at healthcare professionals to enhance their understanding of new products and medical practices. In 2023 alone, the company hosted over \u003cstrong\u003e50 workshops\u003c\/strong\u003e across different regions, attracting approximately \u003cstrong\u003e2,500 healthcare providers\u003c\/strong\u003e and resulting in a measurable improvement in product adoption rates post-workshop.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Relationship Aspect\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n    \u003cth\u003eStatistics\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Engagement through Medical Representatives\u003c\/td\u003e\n    \u003ctd\u003eActive promotion and personalized interaction with healthcare professionals\u003c\/td\u003e\n    \u003ctd\u003eOver \u003cstrong\u003e1,000\u003c\/strong\u003e representatives employed\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCustomer Support Services\u003c\/td\u003e\n    \u003ctd\u003e24\/7 hotline for inquiries and concerns\u003c\/td\u003e\n    \u003ctd\u003eHandled approximately \u003cstrong\u003e150,000\u003c\/strong\u003e inquiries in 2022; \u003cstrong\u003e90%\u003c\/strong\u003e first contact resolution rate\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLoyalty Programs for Healthcare Providers\u003c\/td\u003e\n    \u003ctd\u003eIncentives based on prescription volumes to retain healthcare providers\u003c\/td\u003e\n    \u003ctd\u003eParticipation increased by \u003cstrong\u003e25%\u003c\/strong\u003e in 2023; Sales increase of \u003cstrong\u003e15%\u003c\/strong\u003e in targeted segments\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEducational Workshops\u003c\/td\u003e\n    \u003ctd\u003eWorkshops aimed at enhancing product knowledge among healthcare professionals\u003c\/td\u003e\n    \u003ctd\u003eHosted over \u003cstrong\u003e50\u003c\/strong\u003e workshops in 2023; Attended by approximately \u003cstrong\u003e2,500\u003c\/strong\u003e healthcare providers\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eGrand Pharmaceutical Group Limited utilizes a multifaceted channel strategy to communicate with and deliver its value proposition effectively. The channels include distributors and wholesalers, pharmacies and hospitals, online platforms, and direct sales teams, each playing a vital role in the company's distribution network.\u003c\/p\u003e\n\n\u003ch3\u003eDistributors and Wholesalers\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical partners with various distributors and wholesalers to expand its reach in the market. In 2022, the company reported that approximately **45%** of its revenue came from sales through these intermediaries. The company has strategic partnerships with over **300** distribution firms, enhancing its market penetration across various regions.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies and Hospitals\u003c\/h3\u003e\n\u003cp\u003ePharmacies and hospitals are critical channels for Grand Pharmaceutical. The company supplies products to over **18,000** pharmacies and **3,500** hospitals. In the financial year ended December 2022, sales through these institutions accounted for about **35%** of total revenue. The company has reported a **12%** growth in hospital sales year-over-year, driven by increasing demand for its pharmaceutical products.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eThe rise of e-commerce has prompted Grand Pharmaceutical to invest in online sales platforms. In 2023, online sales reached up to **20%** of the total revenue, indicating a significant shift in consumer behavior. The company collaborates with major e-commerce platforms in China, with an estimated market value of **$140 billion** for pharmaceutical e-commerce in the region. Furthermore, Grand Pharmaceutical's online sales saw a remarkable **30%** growth compared to the previous year.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Teams\u003c\/h3\u003e\n\u003cp\u003eDirect sales teams are pivotal for establishing relationships with key clients, particularly in the healthcare sector. Grand Pharmaceutical employs a force of approximately **1,500** sales representatives dedicated to engaging directly with healthcare professionals. As of 2023, these teams contributed **25%** of total revenue, focusing on personalized sales strategies and responsiveness. Sales from direct channels have grown **15%** annually, underscoring the effectiveness of this approach.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChannel\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n    \u003cth\u003eNumber of Clients\/Partners\u003c\/th\u003e\n    \u003cth\u003eGrowth Rate (%) YoY\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDistributors and Wholesalers\u003c\/td\u003e\n    \u003ctd\u003e45%\u003c\/td\u003e\n    \u003ctd\u003e300\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmacies and Hospitals\u003c\/td\u003e\n    \u003ctd\u003e35%\u003c\/td\u003e\n    \u003ctd\u003e18,000 pharmacies\u003cbr\u003e3,500 hospitals\u003c\/td\u003e\n    \u003ctd\u003e12%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Platforms\u003c\/td\u003e\n    \u003ctd\u003e20%\u003c\/td\u003e\n    \u003ctd\u003eMajor e-commerce platforms in China\u003c\/td\u003e\n    \u003ctd\u003e30%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Sales Teams\u003c\/td\u003e\n    \u003ctd\u003e25%\u003c\/td\u003e\n    \u003ctd\u003e1,500\u003c\/td\u003e\n    \u003ctd\u003e15%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThrough these channels, Grand Pharmaceutical Group Limited effectively communicates its value propositions, facilitating broad access to its diverse product offerings while responding to market demands and changes in consumer behavior.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eGrand Pharmaceutical Group Limited operates within a multi-faceted healthcare environment, targeting various customer segments to optimize its market reach and value propositions.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eThis segment represents a significant portion of Grand Pharmaceutical Group's revenue. In 2022, Grand Pharmaceutical reported that approximately \u003cstrong\u003e40%\u003c\/strong\u003e of its total sales were derived from hospitals and clinics. These institutions utilize a range of products, including prescription medications, vaccines, and specialized therapies.\u003c\/p\u003e\n\u003cp\u003eThe Chinese healthcare market for hospitals is expected to grow at a compound annual growth rate (CAGR) of \u003cstrong\u003e12.5%\u003c\/strong\u003e from 2023 to 2028, reaching an estimated market value of \u003cstrong\u003eUSD 24 billion\u003c\/strong\u003e by 2028. Grand Pharmaceutical's strategic partnerships with over \u003cstrong\u003e8,000\u003c\/strong\u003e hospitals in China position it to leverage this growth effectively.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\u003cp\u003eRetail pharmacies play a crucial role in the distribution of Grand Pharmaceutical's products. In 2022, retail pharmacies contributed around \u003cstrong\u003e30%\u003c\/strong\u003e to the total revenue. The retail pharmacy sector in China was valued at approximately \u003cstrong\u003eUSD 26 billion\u003c\/strong\u003e in 2022, growing at a CAGR of \u003cstrong\u003e10%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eGrand Pharmaceutical has developed strategic relationships with more than \u003cstrong\u003e50,000\u003c\/strong\u003e retail pharmacies across the country. This extensive network facilitates the distribution of its over-the-counter medications and health products.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\u003cp\u003eThe government health department segment is vital for the company's public health initiatives and product offerings. Grand Pharmaceutical has secured numerous government contracts, contributing around \u003cstrong\u003e15%\u003c\/strong\u003e of its annual revenue. In 2023, the government healthcare expenditure in China is projected to exceed \u003cstrong\u003eUSD 1 trillion\u003c\/strong\u003e, with a focus on enhancing pharmaceutical access.\u003c\/p\u003e\n\u003cp\u003eWith ongoing collaborations and compliance with national health policies, Grand Pharmaceutical aims to increase its market share in this segment, which currently encompasses more than \u003cstrong\u003e1,200\u003c\/strong\u003e health departments nationwide.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Organizations\u003c\/h3\u003e\n\u003cp\u003eResearch organizations represent a niche but growing customer segment for Grand Pharmaceutical. The company allocates approximately \u003cstrong\u003e15%\u003c\/strong\u003e of its resources towards partnerships with research institutions and universities for drug development. The global pharmaceutical R\u0026amp;D spending is projected to reach \u003cstrong\u003eUSD 202 billion\u003c\/strong\u003e in 2023, indicating a growing opportunity.\u003c\/p\u003e\n\u003cp\u003eIn 2022, Grand Pharmaceutical collaborated with over \u003cstrong\u003e100\u003c\/strong\u003e research organizations, focusing on innovative therapies and clinical trials that are integral to its product pipeline.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Segment\u003c\/th\u003e\n        \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n        \u003cth\u003eMarket Value (2022)\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate (CAGR)\u003c\/th\u003e\n        \u003cth\u003eStrategic Partnerships\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\n\u003cstrong\u003eUSD 24 billion\u003c\/strong\u003e (by 2028)\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e12.5%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e8,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003eUSD 26 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e50,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGovernment Health Departments\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\n\u003cstrong\u003eUSD 1 trillion\u003c\/strong\u003e (2023)\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1,200\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Organizations\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\n\u003cstrong\u003eUSD 202 billion\u003c\/strong\u003e (R\u0026amp;D spending)\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eGrand Pharmaceutical Group Limited incurs significant costs that are essential for its operations and business model. Below are key components of its cost structure:\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003cp\u003eIn the fiscal year 2022, Grand Pharmaceutical Group Limited allocated approximately \u003cstrong\u003eRMB 1.4 billion\u003c\/strong\u003e toward research and development (R\u0026amp;D). This represented about \u003cstrong\u003e15% of its total revenue\u003c\/strong\u003e, reflecting the company's commitment to innovation and new product development. The allocation for R\u0026amp;D has been increasing annually, with a \u003cstrong\u003e20% year-on-year growth\u003c\/strong\u003e noted compared to 2021.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing costs for Grand Pharmaceutical varied over recent years. In 2022, the total cost of goods sold (COGS) was reported at \u003cstrong\u003eRMB 8.5 billion\u003c\/strong\u003e, which includes raw materials, labor, and overhead. The gross profit margin stood at approximately \u003cstrong\u003e55%\u003c\/strong\u003e, indicating robust manufacturing efficiency. Manufacturing costs are influenced by fluctuations in raw material prices and production volume changes.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance Costs\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical Group faces stringent regulatory requirements across different markets. The costs associated with regulatory compliance were approximated at \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e in 2022, incorporating expenses for audits, quality assurance, and product registration. This marks a \u003cstrong\u003e10% increase\u003c\/strong\u003e from the previous year, highlighting the rising costs in regulatory adherence as the company expands its market presence.\u003c\/p\u003e\n\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003cp\u003eSales and marketing expenditures for Grand Pharmaceutical grouped around \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e in 2022. This amount accounts for approximately \u003cstrong\u003e7% of total revenue\u003c\/strong\u003e. The strategic focus on brand positioning and market penetration has led to a \u003cstrong\u003e15% increase\u003c\/strong\u003e in this area compared to 2021.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCost Component\u003c\/th\u003e\n    \u003cth\u003e2022 Amount (RMB)\u003c\/th\u003e\n    \u003cth\u003eYear-on-Year Growth (%)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch and Development\u003c\/td\u003e\n    \u003ctd\u003e1.4 billion\u003c\/td\u003e\n    \u003ctd\u003e20%\u003c\/td\u003e\n    \u003ctd\u003e15%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n    \u003ctd\u003e8.5 billion\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003ctd\u003e45%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n    \u003ctd\u003e200 million\u003c\/td\u003e\n    \u003ctd\u003e10%\u003c\/td\u003e\n    \u003ctd\u003e2%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSales and Marketing\u003c\/td\u003e\n    \u003ctd\u003e600 million\u003c\/td\u003e\n    \u003ctd\u003e15%\u003c\/td\u003e\n    \u003ctd\u003e7%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese cost elements collectively shape the financial landscape of Grand Pharmaceutical Group Limited, influencing profitability and strategic decision-making within the organization.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGrand Pharmaceutical Group Limited - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eGrand Pharmaceutical Group Limited primarily generates revenue through various streams, which can be categorized as follows:\u003c\/p\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eIn the fiscal year 2022, Grand Pharmaceutical Group reported total product sales of approximately \u003cstrong\u003eRMB 3.2 billion\u003c\/strong\u003e, reflecting a year-over-year growth of \u003cstrong\u003e15%\u003c\/strong\u003e. The company’s portfolio includes prescription drugs, over-the-counter (OTC) products, and medical devices, contributing significantly to their overall revenue. Pharmaceuticals constituted the majority of the sales, with oncology products alone generating around \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing and Royalties\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical engages in licensing agreements with various international pharmaceutical firms. In 2022, the company recorded licensing income of approximately \u003cstrong\u003eRMB 450 million\u003c\/strong\u003e, primarily derived from licensing rights for proprietary drugs in overseas markets. This income is crucial, representing about \u003cstrong\u003e14%\u003c\/strong\u003e of the total revenue in 2022. These agreements often include upfront fees, milestone payments, and royalties based on sales.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Grants\u003c\/h3\u003e\n\u003cp\u003eResearch and development play a vital role in the company's growth strategy. In 2022, Grand Pharmaceutical secured research grants totaling \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e from governmental and non-governmental organizations. These grants support various projects, particularly in the fields of biotechnology and innovative drug development. The funds are critical in accelerating research activities and reducing reliance on internal funding.\u003c\/p\u003e\n\n\u003ch3\u003eStrategic Partnerships and Collaborations\u003c\/h3\u003e\n\u003cp\u003eGrand Pharmaceutical has strategically partnered with several academic institutions and biotechnology companies to advance its product pipeline. These partnerships have generated collaborative revenue amounting to \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e in the last fiscal year. Collaborations often focus on co-development of new drugs and sharing of research costs, which enhances financial stability while fostering innovation.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRevenue Stream\u003c\/th\u003e\n    \u003cth\u003e2022 Revenue (RMB)\u003c\/th\u003e\n    \u003cth\u003eContribution to Total Revenue (%)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct Sales\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLicensing and Royalties\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e450 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e14%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch Grants\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e200 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStrategic Partnerships\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e300 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45663648252053,"sku":"0512hk-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/0512hk-business-model-canvas.png?v=1739114054","url":"https:\/\/dcf-model.com\/fr\/products\/0512hk-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}